Substance / Medication

Fludarabine phosphate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Chronic lymphoid leukemia

Non-Hodgkin's lymphoma (clinical)

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.

Cazin Bruno, Divine Marine, Leprêtre Stéphane et al. · Br J Haematol · 2008

PMID: 18710390Trial

Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma.

Ogawa Y, Hotta T, Tobinai K et al. · Ann Oncol · 2006

PMID: 16275653Trial

Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.

Hagenbeek Anton, Eghbali Houchingue, Monfardini Silvio et al. · J Clin Oncol · 2006

PMID: 16575010Trial

Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.

Dasgupta R K, Rule S, Johnson P et al. · Bone Marrow Transplant · 2006

PMID: 16435017Trial

Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.

Tobinai Kensei, Watanabe Takashi, Ogura Michinori et al. · J Clin Oncol · 2006

PMID: 16330664Trial

Fludarabine phosphate-CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: a dose-finding study.

Soubeyran Pierre, Monnereau Alain, Eghbali Houchingue et al. · Eur J Cancer · 2005

PMID: 16253502Trial

Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.

Rossi J-F, van Hoof A, de Boeck K et al. · J Clin Oncol · 2004

PMID: 15051774Trial

Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.

Klasa Richard J, Meyer Ralph M, Shustik Chaim et al. · J Clin Oncol · 2002

PMID: 12488409Trial

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.

Jackson G, Taylor P, Smith G M et al. · Br J Haematol · 2001

PMID: 11167793Trial

The bioavailability of oral fludarabine phosphate is unaffected by food.

Oscier D, Orchard J A, Culligan D et al. · Hematol J · 2001

PMID: 11920267Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Fludarabine phosphate (substance)
SNOMED CT: 108765002
UMLS CUI: C0060483

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.